Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.

about

New combinations in the treatment of COPD: rationale for aclidinium-formoterol Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.

P2860

Q26765303-2E32F079-AED1-4BE1-A39D-AFD88D31F16C Q38740756-A73D5132-861F-44A1-B431-B542CB68FB61

P2860

Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.

Item

http://www.wikidata.org/entity/Q38586322

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dual bronchodilator therapy wi ...... obstructive pulmonary disease.

@en

type

Item

label

Dual bronchodilator therapy wi ...... obstructive pulmonary disease.

@en

prefLabel

Dual bronchodilator therapy wi ...... obstructive pulmonary disease.

@en

P1476

Dual bronchodilator therapy wi ...... obstructive pulmonary disease.

@en

P2093

David Price

http://www.w3.org/2001/XMLSchema#string

Edward Kerwin

http://www.w3.org/2001/XMLSchema#string

James F Donohue

http://www.w3.org/2001/XMLSchema#string

Tony D'Urzo

http://www.w3.org/2001/XMLSchema#string

P2860

The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population.

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology.

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

P304

519-532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17476348.2015.1081065

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marc Miravitlles

P577

2015-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26366803

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.

about

P2860

P2860

Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921